^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Non-nucleoside reverse transcriptase inhibitor

    Related drugs:
    4d
    Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. (PubMed, J Antimicrob Chemother)
    A three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate maintained durable long-term viral suppression, while mitigating but not fully preventing toxicities associated with EFV/TDF/FTC. These findings support reduced-exposure antiretroviral therapy and warrant evaluation of similar strategies with modern integrase inhibitor-based regimens.
    Clinical • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    6d
    “MOCHA” More Options for Children and Adolescents (clinicaltrialsregister.eu)
    P1/2, N=155, National Institute of Allergy and Infectious Diseases, Division of AIDS
    New P1/2 trial
    13d
    Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting
    Enrollment closed
    16d
    Study on the Effect of Antiretroviral Therapy Centered on Enovirine on PD-1 Expression of CD8+ T Cells Induced by Cholesterol (ChiCTR2500113428)
    P4, N=150, Completed, Xixi Hospital of Hangzhou; Xixi Hospital of Hangzhou
    New P4 trial
    |
    efavirenz
    17d
    Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV (clinicaltrials.gov)
    P1, N=26, Completed, University of Texas Southwestern Medical Center | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Dec 2025 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    20d
    LACRIS: Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study (clinicaltrials.gov)
    P=N/A, N=250, Not yet recruiting, Pomeranian Medical University Szczecin
    New trial • Real-world evidence
    2ms
    ATLAS: Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (clinicaltrials.gov)
    P3, N=618, Active, not recruiting, ViiV Healthcare | Trial completion date: Dec 2025 --> Dec 2029
    Trial completion date • Head-to-Head
    2ms
    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=214, Recruiting, ViiV Healthcare | Trial completion date: Nov 2027 --> Jun 2027 | Trial primary completion date: Jul 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    2ms
    IM-CAPABLE: IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas (clinicaltrials.gov)
    P=N/A, N=55, Recruiting, University of Nebraska | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    3ms
    Retroelements in thyroid cancer: epigenetic plasticity, dedifferentiation, and therapeutic opportunities. (PubMed, Rev Endocr Metab Disord)
    Emerging data also indicate that reverse transcriptase inhibitors (e.g., lamivudine, nevirapine) can partially suppress retroelement activity, induce transcriptional reprogramming and restore radioiodine uptake in refractory thyroid tumors, highlighting a potential therapeutic vulnerability. By integrating cancer epigenetics and mobilome biology, this review reframes thyroid tumor evolution as a process shaped not only by genetic alterations but also by retroelement-mediated disruption of genome regulation. Retroelements may serve as biomarkers of aggressive transformation and as actionable targets in translational oncology.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase)
    3ms
    Association of HPV on risk of HIV acquisition in african women: Analyses from MTN-020/ASPIRE. (PubMed, J Natl Cancer Inst)
    HPV clearance-related immune activation is strongly linked to HIV acquisition, likely due to increased CD4+ T cells and inflammation. These findings support HPV vaccination as a potential HIV prevention strategy and highlight the need to integrate HIV prevention into cervical cancer programs.
    Journal
    |
    CD4 (CD4 Molecule)
    3ms
    REPURPOSE: Phase II study of Efavirenz in platinum resistant or heavily pretreated high-grade serous ovarian cancer (ACTRN12625001259437)
    P2, N=48, Not yet recruiting, The University of Newcastle
    New P2 trial • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    efavirenz